EQL Pharma AB (publ) (STO:EQL)
Sweden · Delayed Price · Currency is SEK | Market Cap | 671.80M -63.3% |
| Revenue (ttm) | 432.35M +8.6% |
| Net Income | -14.04M |
| EPS | -0.47 |
| Shares Out | 29.53M |
| PE Ratio | n/a |
| Forward PE | 17.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,893 |
| Open | 20.90 |
| Previous Close | 21.35 |
| Day's Range | 20.90 - 23.80 |
| 52-Week Range | 17.38 - 67.50 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About EQL Pharma AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden. [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2026, EQL Pharma AB's revenue was 432.66 million, an increase of 15.83% compared to the previous year's 373.52 million. Earnings were 12.54 million, a decrease of -70.93%.
Financial StatementsNews
EQL Pharma AB Transcript: DNB Carnegie Micro Cap Day Conference
The seminar highlighted a shift from rapid growth to operational efficiency, with a focus on resolving supply chain issues, upgrading launch processes, and expanding into new markets. Key branded products are driving growth, and management is optimistic about recovery and future profitability.
EQL Pharma AB Transcript: Q1 26/27
Sales and gross margin were significantly impacted by a SEK 20 million scrapping item, but management expects recovery in Q2 and Q3 as inventory issues are resolved and new product launches progress. Liquidity remains stable with no plans for an equity issue.
EQL Pharma AB Quarterly report: Q1 2027
EQL Pharma AB has published its Q1 2027 quarterly earnings report on August 7, 2026.
EQL Pharma AB Slides: Q1 2027
EQL Pharma AB has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 7, 2026.
EQL Pharma AB Transcript: Q4 25/26
Q4 saw 6% revenue growth but a sharp drop in gross margin due to one-offs and supply chain issues. Management guides for 15% sales growth next year, below long-term targets, as launch delays and operational challenges persist.
EQL Pharma AB Quarterly report: Q4 2026
EQL Pharma AB has published its Q4 2026 quarterly earnings report on May 8, 2026.
EQL Pharma AB Annual report: Q4 2026
EQL Pharma AB has published its Q4 2026 annual report on May 8, 2026.
EQL Pharma AB Transcript: Q3 25/26
Quarterly sales hit a record SEK 190 million, up 29% year-over-year, with gross margin at 42% and EBITA margin at 21%. Supply chain improvements and major launches are expected to drive growth next year, while cost-saving initiatives and process upgrades are underway.
EQL Pharma AB Quarterly report: Q3 2026
EQL Pharma AB has published its Q3 2026 quarterly earnings report on February 4, 2026.
EQL Pharma AB Transcript: Q2 25/26
Q2 saw minimal sales growth and a sharp drop in margins due to supply disruptions, with key product launches delayed. Management is implementing new systems and processes to address operational challenges and expects gradual recovery, targeting 15% sales growth and 20% EBITDA margin for the year.
EQL Pharma AB Quarterly report: Q2 2026
EQL Pharma AB has published its Q2 2026 quarterly earnings report on November 5, 2025.